ijms-logo

Journal Browser

Journal Browser

Special Issue "Biomarkers in Inflammatory and Chronic Degenerative Diseases"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 31 December 2021.

Special Issue Editors

Prof. Dr. Giuseppe Rengo
E-Mail Website
Guest Editor
Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
Interests: heart failure; sympathetic nervous system; ageing; beta-adrenergic receptors; biomarkers; cardiac remodeling; frailty
Special Issues and Collections in MDPI journals
Prof. Dr. Gilda Varricchi,
E-Mail Website
Co-Guest Editor
Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
Interests: biomarkers of allergic disorders; autoimmune diseases and primary immunodeficiencies
Prof. Dr. Alberto Maria Marra
E-Mail
Co-Guest Editor
Department of Pneumology, Centre for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Röntgenstraße 1, Heidelberg 69126, Germany
Interests: pulmonary hypertension; right heart function; right heart failure

Special Issue Information

Dear Colleagues,

Inflammatory and chronic degenerative diseases are the leading causes of death and disability worldwide, and their burden is accelerating, advancing across every country. These diseases significantly affect the quality of life of patients and caregivers, as well as constitute a huge expense for health systems.

The field of biomarker research is globally expanding to improve the management of patients with inflammatory and chronic pathologies, with a specific focus on disease progression and response to therapies. Molecular biology and molecular medicine support even more the evaluation of physiological and pathogenic processes or therapeutic effectiveness.

Accordingly, their employment is being implemented in the clinical practice for early diagnosis and for the development of novel therapeutic targets to better prevent and manage inflammatory and chronic diseases. Further, biomarkers may be useful in monitoring the effect of actions aimed at ameliorating patients’ management and at optimizing the allocation of resources.

One of the critical points of these degenerative conditions is represented by the limits in the early identification of disease reactivation, and even diagnostic criteria are burdened with the complexity of real-world patients (i.e., high number of comorbidities). In this context, the application of biomarkers is extremely relevant in order to implement diagnosis accuracy, specificity, and sensitivity.

In recent decades, several underlying molecular mechanisms of chronic diseases have been recognized, including low-grade inflammation, allowing the identification of novel therapeutic approaches and biomarkers. Thus, this Special Issue in IJMS will cover a selection of recent investigations and current review articles focused on the identification and application of biomarkers in the management of inflammatory and chronic degenerative diseases, such as cardiovascular, immunological, musculoskeletal, and neurodegenerative disorders. We kindly invite researchers to submit manuscripts regarding novel signaling pathways with relevant implication in the pathophysiology of inflammatory and chronic diseases, which may have a direct potential impact in the management of these patients.

Prof. Dr. Giuseppe Rengo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic degenerative diseases
  • low grade inflammation
  • inflammatory diseases
  • biomarkers
  • signaling pathways
  • molecular mechanisms

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Selected Biomarkers of Tick-Borne Encephalitis: A Review
Int. J. Mol. Sci. 2021, 22(19), 10615; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms221910615 - 30 Sep 2021
Viewed by 234
Abstract
Tick-borne encephalitis (TBE) is an acute disease caused by the tick-borne encephalitis virus. Due to the viral nature of the condition, there is no effective causal treatment for full-blown disease. Current and nonspecific TBE treatments only relieve symptoms. Unfortunately, the first phase of [...] Read more.
Tick-borne encephalitis (TBE) is an acute disease caused by the tick-borne encephalitis virus. Due to the viral nature of the condition, there is no effective causal treatment for full-blown disease. Current and nonspecific TBE treatments only relieve symptoms. Unfortunately, the first phase of TBE is characterized by flu-like symptoms, making diagnosis difficult during this period. The second phase is referred to as the neurological phase as it involves structures in the central nervous system—most commonly the meninges and, in more severe cases, the brain and the spinal cord. Therefore, it is important that early markers of TBE that will guide clinical decision-making and the choice of treatment are established. In this review, we performed an extensive search of literature reports relevant to biomarkers associated with TBE using the MEDLINE/PubMed database. We observed that apart from routinely determined specific immunoglobulins, free light chains may also be useful in the evaluation of intrathecal synthesis in the central nervous system (CNS) during TBEV infection. Moreover, selected metalloproteinases, chemokines, or cytokines appear to play an important role in the pathogenesis of TBE as a consequence of inflammatory reactions and recruitment of white blood cells into the CNS. Furthermore, we reported promising findings on tau protein or Toll-like receptors. It was also observed that some people may be predisposed to TBE. Therefore, to understand the role of selected tick-borne encephalitis biomarkers, we categorized these factors and discussed their potential application in the diagnosis, prognosis, monitoring, or management of TBE. Full article
(This article belongs to the Special Issue Biomarkers in Inflammatory and Chronic Degenerative Diseases)
Show Figures

Figure 1

Review
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Int. J. Mol. Sci. 2021, 22(6), 2805; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22062805 - 10 Mar 2021
Cited by 1 | Viewed by 1118
Abstract
Since 2015, 170 small molecules, 60 antibody-based entities, 12 peptides, and 15 gene- or cell-therapies have been approved by FDA for diverse disease indications. Recent advancement in medicine is facilitated by identification of new targets and mechanisms of actions, advancement in discovery and [...] Read more.
Since 2015, 170 small molecules, 60 antibody-based entities, 12 peptides, and 15 gene- or cell-therapies have been approved by FDA for diverse disease indications. Recent advancement in medicine is facilitated by identification of new targets and mechanisms of actions, advancement in discovery and development platforms, and the emergence of novel technologies. Early disease detection, precision intervention, and personalized treatments have revolutionized patient care in the last decade. In this review, we provide a comprehensive overview of current and emerging therapeutic modalities developed in the recent years. We focus on nine diseases in three major therapeutics areas, diabetes, autoimmune, and neurological disorders. The pathogenesis of each disease at physiological and molecular levels is discussed and recently approved drugs as well as drugs in the clinic are presented. Full article
(This article belongs to the Special Issue Biomarkers in Inflammatory and Chronic Degenerative Diseases)
Show Figures

Figure 1

Review
Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review
Int. J. Mol. Sci. 2021, 22(5), 2627; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22052627 - 05 Mar 2021
Cited by 2 | Viewed by 833
Abstract
The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened [...] Read more.
The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened by a remarkable mortality rate, up to 34% in severely ill patients presenting with hemodynamic instability. Initial mortality risk stratification is based on hemodynamic instability. Patients with a situation of hemodynamic stability require immediate further risk assessment based on clinical, imaging, and circulating biomarkers, as well as the presence of comorbidities. Some inflammatory biomarkers have shown potential usefulness in the risk stratification of patients with VTE, especially acute PE. C-reactive protein on admission is associated with 30-day mortality and bleeding in VTE patients. P-selectin is associated with right ventricle dysfunction in PE patients and might be associated with VTE recurrences and the extension of thrombosis. Tissue factor microparticles are associated with VTE recurrence in cancer-associated thrombosis. Other inflammatory biomarkers present scarce evidence (inflammatory cytokines, erythrocyte sedimentation rate, fibrinogen, leukocyte count). In this manuscript, we will review the prognostic role of different inflammatory biomarkers available both for clinical practice and research in VTE patients. Full article
(This article belongs to the Special Issue Biomarkers in Inflammatory and Chronic Degenerative Diseases)
Show Figures

Figure 1

Back to TopTop